drugset / Trial / NCT05668754

Study of SDX in Patients With Idiopathic Hypersomnia (IH)

NCT05668754

Phase 2 Completed 66 enrolled Zevra Therapeutics Rho, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study of the safety, efficacy and pharmacokinetics (PK) of Serdexmethylphenidate (SDX) compared to placebo in subjects with Idiopathic Hypersomnia (IH).

Timeline

Start
2022-12-28
Primary completion
2024-02-28
Completion
2024-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Serdexmethylphenidate Small molecule 80 mg Oral
Subject Serdexmethylphenidate Small molecule 160 mg Oral
Subject Serdexmethylphenidate Small molecule 240 mg Oral
Subject Serdexmethylphenidate Small molecule 320 mg Oral